Novel roles of Hakai in cell proliferation and oncogenesis by Figueroa, A. et al.
Molecular Biology of the Cell
Vol. 20, 3533–3542, August 1, 2009
Novel Roles of Hakai in Cell Proliferation
and Oncogenesis
Ange´lica Figueroa,* Hirokazu Kotani,† Yoshinobu Toda,†
Krystyna Mazan-Mamczarz,‡ Eva-Christina Mueller,§ Albrecht Otto,§
Lena Disch,* Mark Norman,* Rasika Mohan Ramdasi,* Mohammed Keshtgar,
Myriam Gorospe,‡ and Yasuyuki Fujita*¶
*MRC Laboratory for Molecular Cell Biology and Cell Biology Unit, ¶Department of Cell and Developmental
Biology, University College London, London WC1E 6BT, United Kingdom; †Center for Anatomical Studies,
Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan; ‡Laboratory of Cellular
and Molecular Biology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224;
§Max-Delbru¨ck-Center for Molecular Medicine, 13125 Berlin, Germany; and Department of Surgery, Royal
Free Hospital, London NW3 2QG, United Kingdom
Submitted August 18, 2008; Revised June 3, 2009; Accepted June 5, 2009
Monitoring Editor: Thomas Sommer
During tumor development, cells acquire multiple phenotypic changes upon misregulation of oncoproteins and tumor
suppressor proteins. Hakai was originally identified as an E3 ubiquitin-ligase for the E-cadherin complex that regulates
cell–cell contacts. Here, we present evidence that Hakai plays a crucial role in various cellular processes and tumorigen-
esis. Overexpression of Hakai affects not only cell–cell contacts but also proliferation in both epithelial and fibroblast
cells. Furthermore, the knockdown of Hakai significantly suppresses proliferation of transformed epithelial cells.
Expression of Hakai is correlated to the proliferation rate in human tissues and is highly up-regulated in human colon and
gastric adenocarcinomas. Moreover, we identify PTB-associated splicing factor (PSF), an RNA-binding protein, as a novel
Hakai-interacting protein. By using cDNA arrays, we have determined various specific PSF-associated mRNAs encoding
proteins that are involved in several cancer-related processes. Hakai affects the ability of PSF to bind these mRNAs, and
expression of PSF short hairpin RNA or a dominant-negative PSF mutant significantly suppresses proliferation of
Hakai-overexpressing cells. Collectively, these results suggest that Hakai is an important regulator of cell proliferation
and that Hakai may be an oncoprotein and a potential molecular target for cancer treatment.
INTRODUCTION
Carcinoma results from a series of transformations in epi-
thelial cells (Hanahan and Weinberg, 2000). During the
transformations, cells acquire several characteristic pheno-
types, including increased cell proliferation, enhanced cell
motility and invasion, and altered cell–cell and cell–substra-
tum adhesions. Disruption of cell–cell contacts is associated
with the transition from adenoma to carcinoma, and loss of
E-cadherin, a crucial membrane protein for the formation of
adherens junctions (Perez-Moreno et al., 2003; Gumbiner, 2005),
has been shown to be involved in this process (Birchmeier and
Behrens, 1994; Cavallaro and Christofori, 2004).
Hakai was originally identified as an E3 ubiquitin-ligase
for the E-cadherin complex (Fujita et al., 2002). Hakai con-
tains Src homology (SH)2, RING-finger, and proline-rich
domains, and it is structurally and functionally related to
c-Cbl, a RING-finger type E3 ubiquitin-ligase for receptor
tyrosine kinases (Joazeiro et al., 1999; Levkowitz et al., 1999).
Tyrosine phosphorylation of the E-cadherin complex by re-
ceptor or nonreceptor tyrosine kinases promotes the binding
to the SH2 domain of Hakai. Subsequently, Hakai acts as an
E3-ligase for the E-cadherin complex and mediates its ubiq-
uitination, endocytosis, and degradation in the lysosomes
(Fujita et al., 2002; Palacios et al., 2005; Shen et al., 2007;
Bonazzi et al., 2008), causing the perturbation of cell–cell
adhesions. At present, this is the only reported function of
Hakai.
However, there are several lines of evidence that suggest
additional roles for Hakai. First, Northern blot analysis re-
vealed that Hakai is ubiquitously expressed in tissues (Fujita
et al., 2002). The Hakai mRNA was detected in spleen and
skeletal muscle where E-cadherin is absent, suggesting that
Hakai may have substrates other than E-cadherin. Second,
many E3-ligases have multiple substrates for ubiquitination
(Maniatis, 1999; Shenoy et al., 2001; Mantovani and Banks,
2003; Li et al., 2004). By ubiquitinating multiple proteins,
these E3-ligases may coordinate and interconnect apparently
distinct cellular processes. Likewise it is plausible that Hakai
also has multiple substrates. Finally, as shown below, Hakai
localizes in the nucleus as well as in the cytoplasm, indicat-
ing possible functional roles at multiple cellular locations.
In the present study, we show that Hakai is involved in
the regulation of cell proliferation in addition to cell–cell
contacts. Hakai can regulate cell proliferation in an E-cad-
herin down-regulation–independent manner. We also dem-
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onstrate that Hakai interacts with PTB-associated splicing
factor (PSF), a multifunctional RNA-binding protein. Hakai
regulates the ability of PSF to bind transcripts, and the
expression of PSF affects proliferation of Hakai-overexpress-
ing cells. Furthermore, we demonstrate that expression of
Hakai is up-regulated in colon and gastric cancer and
present data suggesting that Hakai is a potential drug target
in cancer treatment.
MATERIALS AND METHODS
Antibodies and Materials
The rabbit polyclonal anti-Hakai antibody (Hakai-2498) was generated by
using peptides (GPHHPDQTRYRPYYQ and DHTDNELQGTNSSG) as anti-
gen (Eurogentec, Seraing, Belgium). Antibody to the cytoplasmic portion of
E-cadherin (BD Biosciences Transduction Labs, Lexington, KY) was used for
Western blotting. Antibodies to the extracellular portion of E-cadherin,
HECD-1 and ECCD-2 (Zymed Laboratories, South San Francisco, CA), were
used for immunofluorescence of human and canine cells, respectively. Anti-
-catenin antibody was from BD Biosceiences Pharmingen. Anti-zona occlu-
dens (ZO)-1 antibody was from Zymed Laboratories. Anti-hemagglutinin
(HA) was from Roche Diagnostics (Mannheim, Germany). Anti-FLAG (M2)
and anti-PSF antibodies were from Sigma-Aldrich (St. Louis, MO). Anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from
Chemicon International (Hampshire, United Kingdom). Anti--tubulin anti-
body was from Immunologicals Direct (Oxford Biotechnology, United King-
dom). Anti-5-bromo-2-deoxyuridine (BrdU) antibody was from Calbiochem
(Darmstadt, Germany). Anti-Ki67 antibody (MM1) was from Novocastra
Laboratories (Newcastle upon Tyne, United Kingdom). Anti-cdk2, anti-cdk4,
anti-cyclin D1, anti-cyclin E, anti-p21, and anti-HuR (3A2) antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-cdk6 antibody was
from Neomarkers (Fremont, CA). Anti-ubiquitin antibody was from BAbCO
(Richmond, CA). All antibodies were used at dilutions of 1:1000 for Western
blotting and 1:100 for immunofluorescence, except for the following antibod-
ies: anti-cdk2 and anti-cdk4 (1:2000), anti-cyclin D1 (1:5000), anti-cyclin E
(1:200), and anti-p21 (1:200) antibodies for Western blotting. pcDNA-HA-
Hakai and pGEX-Hakai (N terminus: amino acids 20-216) were kindly pro-
vided by Walter Birchmeier (Max-Delbru¨ck-Center, Berlin, Germany) (Fujita
et al., 2002). pEGFP-PSF (full length), -PSF-N (amino acids 1-340), -PSF-C
(amino acids 338-707), and -PSF-RRM2 (RNA recognition motif) were kindly
provided by James G. Patton (Vanderbilt University, Nashville, TN) (Dye and
Patton, 2001). To construct the Hakai mutant (Hakai-RING: amino acids
1-108 and 147-491) lacking the RING-finger domain, cDNAs of the Hakai N-
and C-terminal domains were amplified by polymerase chain reaction (PCR)
using the following primers: for the N terminus, 5-GGA ATT CGG CCG GAT
CAC ACT GAC AAT GAG TTA CAA GG-3 and 5-GGA ATT CGC GGC
CGC GAA ATG TAC TGG TGT ATC GTC CTT TTC-3; for the C terminus,
5-GGA ATT CGG CCG GAT GTA GTG ATC CTG TGC AGC GGA TTG-3
and 5-GGA ATT CGC GGC CGC TCA CTG GTA ATA CGG TCT GTA TCT
TGT TTG ATC-3. The cDNA of the Hakai N terminus was cleaved by EagI
and cloned into a NotI site of pcDNA-HA. Then, the cDNA of the Hakai C
terminus was cleaved by EagI and cloned into a NotI site of pcDNA-HA-
Hakai-N-terminus. The hepatocyte growth factor (HGF)/scatter factor was
purchased from Chemicon International.
Cell Culture, Western Blotting, Immunoprecipitation,
Immunofluorescence, Time-Lapse Analysis, and Affinity
Protein Purification
Human embryonic kidney (HEK)293, Madin-Darby canine kidney (MDCK),
MCF-7, MDA-MB231, NIH3T3, and A431 cells were cultured in DMEM
containing penicillin/streptomycin and 10% fetal calf serum (FCS) at 37°C
and ambient air supplemented with 5% CO2. MCF-10A cells were cultured in
DMEM/F-12 containing penicillin/streptomycin, 5% horse serum, 20 ng/ml
epidermal growth factor (Millipore, Billerica, MA), 0.5 g/ml hydrocortisone
(Calbiochem), 100 ng/ml cholera toxin (Sigma-Aldrich), and 10 g/ml Insulin
(Invitrogen, Paisley, United Kingdom) at 37°C and ambient air supplemented
with 5% CO2. To establish cell lines stably expressing Hakai, MDCK cells
were transfected with pcDNA-HA-Hakai using Lipofectamine Plus reagent
(Invitrogen) and were selected in a medium containing 800 g ml1 G418
(Calbiochem). More than 10 stable clones were obtained from two indepen-
dent transfections. All clones represented comparable phenotypes and results
using clone 4 were presented if not indicated. Western blotting, immunopre-
cipitation, and immunofluorescence were performed as described previously
(Hogan et al., 2004). For Western blotting, cell lysates (30 g of proteins) were
loaded in SDS-polyacrylamide gel electrophoresis (PAGE) if not indicated.
For immunoprecipitation, we used 1% Triton X-100 lysis buffer (20 mM
Tris-HCl pH 7.5, 150 mM NaCl, and 1% Triton X-100) containing 5 g ml1
leupeptin, 50 mM phenylmethylsulfonyl fluoride, and 7.2 trypsin inhibitor
units of aprotinin. For Supplemental Figure S8, 10 mM N-ethylmaleimide
(Sigma-Aldrich) was added in lysis buffer. Immunofluorescence images were
analyzed by epifluorescence microscopy, if not indicated. For Supplemental
Figure S1, human fibronectin-coated coverslips (BD Biosciences, Erembode-
gem, Belgium) were used for immunofluorescence. To visualize nuclei, we
used Hoechst 33342 (Invitrogen). Cell death was measured by using LIVE/
DEAD Viability/Cytotoxicity kit (Invitrogen) according to manufacturer’s
instructions. To obtain epifluorescence images, we used an Axioskop 1 (Carl
Zeiss, Jena, Germany) with a CoolSNAP camera (Roper Scientific, Trenton,
NJ). To obtain phase contrast images, we used a DMIRB microscope (Leica,
Wetzlar, Germany) with a C4742-95 Orca camera (Hamamatsu, Bridgewater,
NJ). For time-lapse experiments, cells were cultured in Leibovitz’s medium
containing 10% FCS during 24 h at 37°C. To obtain time-lapse images we used
an Axiovert 100M microscope (Carl Zeiss) with a Biopoint Controller (Ludl
Electronic Products, Hawthrorne, NY) and a C4742–95 Orca camera
(Hamamatsu). Time-lapse images were captured and analyzed using Openlab
software (Improvision, Coventry, United Kingdom). For Figures 1B and 7C,
confocal images were captured using a TCS SPE confocal microscope and
Leica Application Suite (Lecia) and were analyzed using ImageJ 1.36b (Na-
tional Institutes of Health, Bethesda, MD). For affinity protein purification,
HEK293 cells from four 15-cm plates (Figure 7A) or transfected HEK293 cells
in a 9-cm dish (Supplemental Figure S6) were lysed in Triton X-100 lysis
buffer, and the cell lysates were subjected to glutathione beads coupled to 20
g of glutathione transferase (GST) or GST-Hakai (N terminus: amino acids
20-216), followed by SDS-PAGE, and Coomassie protein staining or Western
blotting. Hakai-binding proteins were excised from the gel. The amino acid
sequences were determined by liquid chromatography-tandem mass spec-
trometry.
Proliferation Assay and Flow Cytometry Analysis
For quantification of the cell number, 2.5  104 cells were plated in a six-well
plate, and the cell number was counted during 5 d using hemocytometer. For
colorimetric analysis, 1  104 cells were plated in a 96-well plate, and after
24 h they were treated with 10 M BrdU for 3 h. BrdU incorporation into
newly synthesized DNA was measured using a cell proliferation colorimetric
immunoassay kit (Calbiochem) according to manufacturer’s instructions. For
the immunofluorescence assay, 5  105 cells were plated in a six-well plate.
After 24 h, cells were transfected if indicated, and they were treated with 10
M BrdU for 5 h for MDCK cells or 3 h for other cell lines. They were fixed
with 3.7% paraformaldehyde/phosphate-buffered saline (PBS) for 15 min and
incubated with 2 N HCl and 0.5% Triton X-100 for 30 min before the primary
antibody incubation. For the flow cytometry analysis, cells were trypsinized,
washed with PBS containing 1 mM EDTA, and fixed with chilled 70% ethanol
for 30 min at 4°C, followed by incubation in PBS containing 100 g/ml
RNase and 50 g/ml propidium iodide (Sigma-Aldrich). Stained DNA
was analyzed by FACSscan flow cytometer (Clontech, Mountain View,
CA). Data were acquired and analyzed by Cell Quest Program (BD Bio-
sciences, Cowley, United Kingdom).
RNA Interference
Oligonucleotides (oligos) used for Hakai siRNA were Hakai-1 (CTCGATCG-
GTCAGTCAGGAAA) and Hakai-2 (CACCGCGAACTCAAAGAACTA). The
small interfering RNA (siRNA) oligos were transfected into MCF-7, MDA-
MB231, or HEK293 cells using HiPerFect reagent (QIAGEN, Dorking, Surrey,
United Kingdom) according to manufacturer’s instructions. Cells (5  104)
were plated in a 24-well plate, and 1.5 g of siRNA was transfected with 9 l
of HiPerFect reagent per well. As a negative control, we used nonsilencing
control siRNA (AF 488) from QIAGEN. At 96 h after transfection, cells were lysed
in Triton X-100 lysis buffer and examined by Western blotting. Hakai-overex-
pressing MDCK cells stably expressing PSF short hairpin RNA (shRNA) were
produced as follows: PSF shRNA oligonucleotides (5-CACCGCAAAGGAT-
TCGGGCTTATTACGAATAATAAGCCCGAATCCTTTGC-3 and 5-AAAA-
GCAAAGGATTCGGGCTTATTATTCGTAATAAGCCCGAATCCTTTGC-3)
were cloned into pENTR/H1/TO using BLOCK-iT Inducible H1 RNAi Entry
Vector kit (Invitrogen) according to manufacturer’s instructions. MDCK HA-
Hakai cells (clone 4) were transfected with pENTR/H1/TO PSF shRNA using
Lipofectamine 2000 (Invitrogen), followed by selection in medium containing
400 g ml1 of Zeocin (Invitrogen) and 800 g ml1 G418. To ensure equal
loading, protein concentration of lysates was quantified using the DC Protein
Assay reagent (Bio-Rad Laboratories, Hercules, CA) and measured by a
VERSAmax microplate reader (Molecular Devices, Sunnyvale, CA).
Immunohistochemistry
Tissue samples for immunohistochemistry were fixed overnight in neutral-
buffered Formalin and embedded in paraffin wax. Immunohistochemistry
was performed on paraffin wax sections as described previously (Toda et al.,
1999). Antigen retrieval was performed by microwave method for anti-Hakai
and anti-E-cadherin antibodies or autoclave method for anti-Ki67 antibody.
For the former, the slides were microwaved in 10 mM citrate buffer, pH 6.0,
for 10 min in a pressure proof cooker (Rakuchin Gozen, Daiya Industries,
Tokyo, Japan), and then placed on a metal rack and boiled for 20 min,
followed by placing into distilled water. For the latter, a Coplin jar containing
glass slides in citrate buffer was covered with a loose fitting cap and heated in
A. Figueroa et al.
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a prestige stainless steel pressure cooker for 5 min at 121°C. The pressure
cooker was then removed from heat source, and the glass slides were rinsed
in distilled water. Endogenous peroxidase activity was then blocked by 0.3%
H2O2 in methyl alcohol for 30 min, followed by washing with PBS. Nonspe-
cific binding was blocked by incubating the sections in 1% goat serum
(Sigma-Aldrich) for 30 min. Polyclonal primary antibodies were diluted at
1:2000 in PBS/1% bovine serum albumin (BSA) and incubated overnight at
4°C, followed by incubation for 30 min with biotinylated secondary antibody
(Vector Laboratories, Burlingame, CA) diluted at 1:300 in PBS. After five
washes with PBS, the avidin-biotin-peroxidase complex (ABC-Elite; Vector
Laboratories) was applied for 50 min at a 1:100 dilution in PBS/1% BSA. After
washing with PBS, coloring reaction was detected with 0.3 mg/ml diamino-
benzidine and 0.003% H2O2 in 50 mM Tris-HCl, pH 7.6. Hematoxylin was
used as a nuclear counterstain. Informed consent was obtained from each
patient.
Soft Agar Anchorage-Independent Growth Assay
To examine anchorage-independent cell growth, we used a colony formation
assay in soft agar. First, 3 ml of DMEM/10% FCS containing 0.5% low-melting
agarose was placed in six-well dishes as a bottom support layer. Then, 1 103
parental or Hakai-overexpressing MDCK cells were suspended in DMEM/
10%FCS containing 0.3% low-melting agarose (Lonza Rockland, Rockland,
ME) and overlaid as a top layer. After 12 d of incubation at 37°C, colonies
were stained with 100 l of 10 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium (Sigma-Aldrich) for 1 h at 37°C.
Analyses of PSF–mRNA Complexes
Immunoprecipitation of PSF-mRNA complexes was performed as described
previously (Mazan-Mamczarz et al., 2006), except that cell lysates were pre-
cleared for 30 min at 4°C using 30 g of mouse immunoglobulin G (IgG)
(Sigma-Aldrich) coupled to 50 l of protein A-Sepharose 4B beads (GE
Healthcare, Chalfont St. Giles, United Kingdom), which had been swollen in
NT2 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl2, and 0.05%
Nonidet P-40) supplemented with 5% bovine serum albumin. From the im-
munoprecipitates, RNAs were extracted and used either for hybridization of
cDNA arrays or for verification of individual PSF target transcripts. The array
analysis was performed as reported previously (Mazan-Mamczarz et al.,
2006). In brief, the RNAs extracted from immunoprecipitates with anti-PSF
antibody or control IgG were reverse transcribed in the presence of
[-33P]dCTP, and the radiolabeled product was used to hybridize cDNA
arrays (Mammalian Gene Collection [MGC] arrays, containing 6000 indi-
vidual human genes) as described previously (Tenenbaum et al., 2002). All of
the data were analyzed using the Array-Pro software (Media Cybernetics,
Carlsbad, CA), and then normalized by Z score transformation and used to
calculate differences in signal intensities. Significant values were tested using
a two-tailed Z-test and p values 0.01 (n  3). It should be noted that human
cDNA arrays were hybridized with cDNAs from canine MDCK cells; there-
fore, it is plausible that some of transcripts might have been missed under this
experimental condition. For the analysis of individual transcripts, the RNAs
from the immunoprecipitation (IP) material were used in reverse transcrip-
tion. Reverse transcription (RT)-PCR was carried out using SuperScript II
reverse transcriptase with random hexamers (Invitrogen). To determine the
mRNA level coding -actin, we used human -actin primers (Invitrogen).
Specific primers were designed to correspond to the target mRNA sequences of
both dog and human: for PAI-RBP1 (5-CCTGGGCACTTACAGGAAGG-3 and
5-CACCCTTTTCTTCAAGTGGC-3); for NF2 (5-GATGCGGTCTGAGGAGA-
CAGC-3 and 5-CTGACTCCTCAGCCATCTTCAG-3); for LKB1 (5-GGA-
CACGTTCATCCACCGCATC-3 and 5-CTTGAGCTTCTTCTTCTTGAG-3);
for -catenin (5-GCCATGTCCCTGATCCAGGC-3 and 5-GCACCGGGTTCA-
CATGCTTCTTC-3); and for tubulin -6 (5-CAAGTGACAAGACCATTGG-3
and 5-CTACCATGAAGGCACAATCAG-3). PCR products were visualized
after electrophoresis in 2% agarose gels stained with ethidium bromide to
verify that a single band was amplified in each reaction. HuR–mRNA com-
plexes were analyzed in the same way as described above, except that
anti-HuR antibody was used for IP.
Statistical Analysis
Student’s t test assuming unequal variance was performed for statistical
analysis.
RESULTS
Subcellular Localization of Hakai in Various Cell Lines
In the previous study, we showed the role of Hakai as an E3
ubiquitin-ligase for the E-cadherin complex (Fujita et al.,
2002). However, the subcellular localization of Hakai still
remains unknown. To determine the localization of endog-
enous Hakai protein, we newly generated polyclonal anti-
body that specifically recognizes Hakai. Expression of en-
dogenous Hakai protein was detected by Western blotting
with this antibody in different cell lines such as MDCK,
MCF-7, and HEK293 cells (see Figure 1D and Supplemental
Figure 3A). The antibody also recognized exogenously ex-
pressed FLAG-tagged Hakai in HEK293 cells (Figure 1A).
Using this antibody, we analyzed the localization of Hakai
in various epithelial cell lines by immunofluorescence. In
nontransformed epithelial cell lines, MDCK and MCF-10A
cells, we observed enriched nuclear localization of Hakai
(Figure 1B). In transformed epithelial cell lines, MCF-7 and
A431 cells, punctuate cytoplasmic localization of Hakai was
observed together with the nuclear distribution (Figure 1B;
data not shown).
Next, we examined whether the localization of Hakai was
affected by addition of growth factor. We analyzed the effect
of HGF, which enhances proliferation, dissociation of cell–
cell contacts and cell motility in epithelial cells (Birchmeier et
al., 2003). After 18 h of HGF treatment, MDCK cells lost
epithelial morphology with disrupted intercellular adhe-
sions and became more fibroblastic (Figure 1C, top). Inter-
Figure 1. Subcellular localization of Hakai in different cell lines.
(A) Detection of exogenous Hakai protein by anti-Hakai antibody.
Cell lysates of HEK293 cells expressing FLAG-tagged Hakai were
immunoprecipitated with anti-FLAG antibody, followed by West-
ern blotting with anti-Hakai antibody. (B) Immunofluorescence
analyses of MDCK, MCF-10A, and MCF-7 epithelial cells using
anti-Hakai antibody. Nuclei were stained with Hoechst dye. Images
were analyzed by confocal microscopy. (C and D) Effect of HGF on
the localization and expression of Hakai in MDCK cells. Cells were
incubated in the presence or absence of HGF (40 ng/ml) for the
indicated times. (C) Cells were examined by phase contrast and
immunofluorescence with anti-Hakai antibody. (D) Cell lysates
were examined by Western blotting with anti-Hakai and anti--
tubulin antibodies. Bars (B and C), 10 m.
Role of Hakai in Proliferation and Oncogenesis
Vol. 20, August 1, 2009 3535
estingly, during this process, the increased cytoplasmic lo-
calization of Hakai was observed (Figure 1C, bottom). We
also found that the expression level of Hakai protein was
enhanced by HGF treatment (Figure 1D). These data suggest
that the localization of Hakai is dynamically regulated under
different conditions.
Overexpression of Hakai Induces Attenuation of Cell–Cell
Adhesions and Enhances Cell Proliferation
To further understand the functional role of Hakai, we
newly established MDCK cell lines stably overexpressing
Hakai. In these cells, the expression of exogenous Hakai was
four- to sixfold higher than that of endogenous Hakai (Sup-
plemental Figure S1C), and twofold higher than that of the
previously established clones (Fujita et al., 2002). Nontrans-
fected parental MDCK cells showed a typical epithelial mor-
phology with tight cell–cell contacts (Supplemental Figure
S1A, left). In contrast, all of the Hakai-overexpressing
MDCK cell lines represented fibroblastic morphology with
decreased cell–cell contacts and increased protrusion forma-
tion (Supplemental Figure S1A, right). Time-lapse micro-
scopic analyses revealed that, compared with parental cells
(Supplemental Movie 1), Hakai-overexpressing cells fre-
quently produced spiky protrusions that were dynamically
extended and retracted (Supplemental Movie 2). Exog-
enously expressed Hakai was localized in the nucleus as
well as in the cytoplasm (Supplemental Figure S1B). In the
cytoplasm, Hakai showed a diffuse and some punctuate
localization and was also enriched at the tip of protrusions
(Supplemental Figure S1B, arrows), suggesting a role in the
protrusion dynamics.
Using these stable cell lines, we examined the effect of
overexpression of Hakai on cell–cell adhesions. In Hakai-
overexpressing cells, the expression of E-cadherin was sub-
stantially reduced (Supplemental Figure S1C) and E-cad-
herin disappeared from cell–cell contacts (Supplemental
Figure S1E). This effect on E-cadherin was greater than that
observed in the previous report (Fujita et al., 2002), probably
because of the higher expression level of Hakai in the newly
established clones. The expression of -catenin (another ad-
herence junction protein) and ZO-1 (tight junction protein)
was not altered in Hakai-overexpressing cells (Supplemental
Figure S1D), and they remained at cell–cell contact sites (Sup-
plemental Figure S1E). This is consistent with a previous report
showing that reducing E-cadherin expression alone has little
effect on the localization of -catenin and ZO-1 in MDCK cells
(Capaldo and Macara, 2007). Our data indicate the specific
effect of Hakai on E-cadherin at cell–cell contacts.
While culturing Hakai-overexpressing MDCK cells, we
also found that they underwent cell division much faster
than parental MDCK cells. We quantified this observation
by counting the number of cells during 5 d of incubation. As
shown in Figure 2A, we found the increased cell number in
Hakai-overexpressing cells. BrdU is a synthetic nucleoside
that is an analogue of thymidine. It is incorporated into
newly synthesized DNA during S phase of the cell cycle and
substitutes for thymidine during DNA replication; thus, it is
commonly used to detect proliferating cells in living tissues.
Using this method, we observed a significant increase in the
proliferation rate of Hakai-overexpressing MDCK cells com-
pared with parental MDCK cells (Figure 2B). As shown in
Supplemental Figure S2, cell death was not decreased in
Hakai-overexpressing cells, indicating that the increased cell
number in Hakai-overexpressing cells is not due to de-
creased cell death. By using flow cytometry, we also exam-
ined the effect of overexpression of Hakai on cell cycle. The
percentage of sub-G0/G1 cell population in parental and
Hakai-overexpressing MDCK cells is 70 and 44%, respec-
tively (Figure 2C), indicating that overexpression of Hakai
promotes the transition from G0/G1 to S phase. Indeed, in
Hakai-overexpressing MDCK cells, the protein expression
level of cell cycle regulators controlling transition from
G0/G1 to S phase was substantially affected (Supplemental
Figure S3A). Overexpression of Hakai also significantly en-
hanced cell proliferation in NIH3T3 fibroblast cells that do
not express E-cadherin (Supplemental Figure S3, B and D),
suggesting that the effect of Hakai occurs in an E-cadherin-
independent manner. Collectively, these data indicate that
overexpression of Hakai induces a higher proliferation rate.
Next, we examined whether E3 ubiquitin-ligase activity of
Hakai is involved in regulation of proliferation. It has been
reported that the RING-finger domain is required for the E3
ligase activity of Hakai (Fujita et al., 2002). Thus, we ana-
lyzed the effect of expression of the Hakai mutant (Hakai-
RING) lacking the RING-finger domain (Supplemental
Figure S4, A–C) on cell proliferation in MDCK cells. We
found that expression of Hakai-RING strongly suppressed
cell proliferation, whereas expression of wild-type Hakai
enhanced it (Supplemental Figure S4D). This result suggests
that E3 ubiquitin-ligase activity of Hakai, at least partially,
plays a role in regulation of cell proliferation.
Figure 2. Effect of overexpression of Hakai on cell proliferation in
MDCK cells. (A and B) Increased proliferation rate in Hakai-over-
expressing MDCK cells. (A) The cell number of parental and Hakai-
overexpressing MDCK cells was monitored during 5 d. (B) Parental
and Hakai-overexpressing MDCK cells were labeled with BrdU,
followed by colorimetric assay. Statistical analyses from nine indepen-
dent experiments indicate the significantly increased BrdU incorpora-
tion in Hakai-overexpressing MDCK cells (p  0.005). (C) Effect of
overexpression of Hakai on cell-cycle regulation. The DNA content of
parental and Hakai-overexpressing MDCK cells was analyzed by flow
cytometry. (A and B) Data are represented as mean  SD.
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Knockdown of Hakai Decreases the Proliferative Rate of
Transformed Epithelial Cells
Next, we examined whether the knockdown of Hakai in
transformed epithelial MCF-7 and HEK293 cells affects their
proliferation rate. The expression of Hakai was strongly
reduced by transiently transfecting either of two different
Hakai-specific siRNA oligos (Figure 3A and Supplemental
Figure S5). Under these experimental conditions, MCF-7 and
HEK293 cells transfected with Hakai siRNA had a signifi-
cantly decreased BrdU incorporation as determined by col-
orimetric assay (Figure 3B). We observed 35–45% reduction
of the BrdU incorporation in MCF-7 cells transfected with
Hakai siRNA, compared with those with control siRNA
(Figure 3B). Furthermore, the effect of Hakai knockdown on
the expression of cell cycle regulators was examined. We
found that the protein expression level of cyclin D1 was
substantially decreased in Hakai-knockdown MCF-7 and
HEK293 cells (Figure 3C). The expression of other cell cycle
regulators or E-cadherin was not affected (Figure 3C), sug-
gesting the specific effect of Hakai knockdown on cyclin D1.
Comparable effect of Hakai knockdown on cyclin D1 was
also observed in MDA-MB231 cells where E-cadherin is not
expressed (Supplemental Figure S3, C and D). Together, we
conclude that Hakai plays a crucial role in the regulation of
cell proliferation.
Enhanced Expression of Hakai in Proliferative Tissues
As shown in Figures 2 and 3, our results indicated a role of
Hakai in cell proliferation in cell culture systems. To ascer-
tain whether Hakai is indeed involved in a proliferation
process in vivo, we investigated the expression and local-
ization of Hakai in different human tissues. First, we ana-
lyzed Hakai expression in endometrium of the uterus.
Throughout the reproductive age, every woman undergoes
a hormonal cycle lasting for an average of 28 d. In this
ovulation cycle, there are two phases in the uterus endome-
trium: proliferative and secretory phases. During the prolif-
erative phase, cells lining the uterine cavity begin to prolif-
erate under the effect of estrogen. In contrast, during the
secretory phase, cells stop proliferating and increase their
secretory activity under the effect of progesterone. Thus, the
endometrium is an excellent model system to analyze the
involvement of proteins in cell proliferation. By immunohis-
tochemistry we observed very low expression of Hakai in
the endometrial cells in the secretory phase (Figure 4A, top
left). This correlated with low expression of Ki67, a prolif-
eration marker (Figure 4A, top right). In contrast, enhanced
expression of Hakai was detected in the proliferative phase
(Figure 4A, bottom left), together with increased Ki67 ex-
Figure 3. Effect of the knockdown of Hakai on cell proliferation in
MCF-7– and HEK293–transformed epithelial cells. (A) Effect of Ha-
kai siRNA in MCF-7 and HEK293 cells. MCF-7 or HEK293 cells were
transiently transfected with either of two different Hakai siRNA
oligos or a control nonsilencing oligo. After 72 h of transfection, cell
lysates were examined by Western blotting with anti-Hakai and
anti-GAPDH antibodies. (B) BrdU incorporation determined by col-
orimetric assay. Transfected MCF-7 or HEK293 cells were labeled
with BrdU, followed by colorimetric assay. Statistical analyses in-
dicate the significantly decreased BrdU incorporation in Hakai-
knockdown MCF-7 cells (*p  0.01, **p  0.005; n  9) or HEK293
cells (*p  0.01, **p  0.00002; n  3). Data are represented as
mean  SD. (C) Effect of Hakai-knockdown on cell cycle regulators.
MCF-7 or HEK293 cells were transiently transfected with a Hakai
siRNA or control nonsilencing oligo. After 72 h of transfection, cell
lysates were examined by Western blotting with antibodies against
various cell cycle regulators.
Figure 4. Hakai expression in human tissues. (A) Sections of se-
cretory and proliferative phases of the uterus endometrium. Immu-
nohistological analyses were performed with anti-Hakai and anti-
Ki67 antibodies (brown) using samples from a secretory phase (top)
and a proliferative phase (bottom) of the endometrium. (B) Sections
of cervical lymph node. The germinal center in the lymph node
shows enhanced Hakai and Ki67 immunoreactivity (brown). (A and
B) Tissues were also stained with hematoxylin (blue). Bars, 50 m.
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pression (Figure 4A, bottom right). Enhanced expression of
Hakai was observed both in the nucleus and cytoplasm.
Expression of E-cadherin remained at a low level during
both secretory and proliferative phases (Supplemental Fig-
ure S6). These data indicate that the expression of Hakai is
highly up-regulated in the proliferative phase of the human
endometrium.
We also analyzed the expression level of Hakai in the
lymph node that contains germinal centers where lympho-
cytes are actively proliferating. There was a marked increase
in Hakai and Ki67 expression in the germinal center (Figure
4B). These results suggest that, at least in the endometrium
and lymph node, the expression of Hakai is up-regulated
where cells proliferate actively, further supporting a role for
Hakai in the proliferation process.
Involvement of Hakai in Oncogenesis
The effects observed in Hakai-overexpressing and Hakai-
knockdown epithelial cells suggested a potential role for
Hakai in tumor progression. By using soft agar assays, we
first examined the colony formation driven by Hakai-over-
expressing cells compared with parental MDCK cells. As
shown in Figure 5, Hakai-overexpressing cells formed col-
ony foci in soft agars, whereas parental MDCK cells did not.
These data indicate that overexpression of Hakai induces
anchorage-independent cell growth; thus, Hakai exhibits an
oncogenic potential. Next, by immunohistochemistry, we
examined the expression and localization of Hakai in human
colon cancer tissues. The section shown in the left panel of
Figure 6A includes normal colon epithelium (left half of the
image) and colon adenocarcinoma (right half of the image)
in the same slide. Immunostaining with anti-Hakai antibody
clearly demonstrated the increased expression of Hakai in
colon adenocarcinoma compared with normal colon epithe-
lium. The magnified images revealed that the expression of
Hakai was enhanced both in the nucleus and the cytoplasm
in colon cancer cells (Figure 6A, right). In Figure 6B, we
showed a section from another patient that also includes
normal colon (right half of the image) and colon adenocar-
cinoma (left half of the image) in the same slide. Immuno-
histochemical analyses with anti-Hakai and anti-Ki67 anti-
bodies showed that both Hakai and Ki67 were highly
expressed in colon adenocarcinoma cells. We have observed
comparable up-regulation of Hakai in all of the four colon
cancer tissues thus far analyzed. The expression of Hakai
was further examined in gastric adenocarcinoma. The sec-
tion shown in Figure 6C includes normal stomach epithe-
lium (arrows) and gastric adenocarcinoma (arrowheads) in
the same slide. Immunostaining with anti-Hakai antibody
showed the increased expression of Hakai in gastric adeno-
carcinoma. The comparable up-regulation of Hakai was ob-
served in 60% of the independent gastric adenocarcinoma
samples (n 5). These data suggest that expression of Hakai
is often enhanced in colon and gastric cancer and is corre-
lated with enhanced proliferation of cancer cells.
Hakai Interacts with PSF and Affects Its RNA-Binding
Ability
We have shown that Hakai induces various phenotypic
changes in epithelial cells. However, not all these changes
can be solely attributed to the decreased expression of E-
cadherin. We have also revealed that Hakai is localized in
the nucleus. Therefore, we further investigated a possible
role of Hakai in the nucleus. To identify novel Hakai-inter-
acting proteins, we performed affinity protein purification
using HEK293 cell lysates with glutathione beads coupled to
GST or GST-Hakai. Two proteins were recovered in GST-
Hakai beads but were not present in GST beads (Figure 7A,
arrow and arrowhead). Mass spectrometric analysis re-
vealed that the novel Hakai-interacting proteins were PSF
and its binding partner p54nrb. We also confirmed the inter-
action between endogenous Hakai and PSF proteins in
HEK293 cells by immunoprecipitation (Figure 7B). Using
several truncation mutants, we showed that the N terminus
of PSF is, at least partially, responsible for the interaction
with Hakai (Supplemental Figure S7). PSF is a RNA-binding
Figure 5. Anchorage independent-growth of Hakai-overexpress-
ing MDCK cells. Cells were suspended in soft agars, and colony
formation was examined after 12 d. The result shown is a represen-
tative of three independent experiments.
Figure 6. Enhanced Hakai expression in colon and gastric cancer
tissues. (A) A section of normal colon epithelium (left half of the
image) and grade I colon adenocarcinoma (right half of the image).
A section was examined by immunohistochemistry using anti-Ha-
kai antibody. Bar, 100 m. Magnified images are shown in the right
panels. Bar, 20 m. (B) Sections of normal colon epithelium (right
half of the image) and grade II colon adenocarcinoma (left half of the
image). Sections were examined by immunohistochemistry using
anti-Hakai and anti-Ki67 antibodies. Bars, 200 m. (C) A section of
normal stomach epithelium (arrows) and grade II gastric adenocar-
cinoma (arrowheads). A section was examined by immunohisto-
chemistry using anti-Hakai antibody. Bar, 20 m. (A–C) Tissues also
were stained with hematoxylin (blue).
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protein that was initially termed as a splicing factor (Patton
et al., 1993), but recently it has been shown to regulate
several cellular processes, including transcription, pre-
mRNA processing, nuclear retention of edited RNA, and
DNA relaxation (Shav-Tal and Zipori, 2002). It contains two
consensus RNA-binding domains; however, only a few mR-
NAs have been reported to bind PSF (Zolotukhin et al., 2003;
Buxade et al., 2008; Cobbold et al., 2008). To investigate the
physiological significance of the interaction between Hakai
and PSF, their subcellular localization was first analyzed in
MCF-7 and MDCK cells by immunofluorescence. We found
that Hakai and PSF are colocalized in the nucleus in both cell
lines (Figure 7C). Overexpression of Hakai did not induce
ubiquitination of PSF as determined by Western blotting
with anti-ubiquitin antibody after immunoprecipitation of
PSF (Supplemental Figure S8), suggesting that PSF is not a
substrate of E3 ubiquitin-ligase Hakai. Next, we examined
whether overexpression of Hakai affects the ability of PSF to
bind RNA. To identify the mRNAs bound to PSF, cell lysates
of parental and Hakai-overexpressing MDCK cells were im-
munoprecipitated with control IgG or anti-PSF antibody,
followed by extraction of mRNAs. The RNAs from the im-
munoprecipitates were then reverse transcribed, and the
resulting products were hybridized to human cDNA arrays
(http://www.grc.nia.nih.gov/branches/rrb/dna/dna.htm#,
MGC arrays). It is interesting that in parental MDCK cells, we
could not detect significant binding of any transcripts to
PSF. In contrast, in Hakai-overexpressing cells, we found
that 176 array spots (2.93% of the total spot on the array)
had -fold increase of 	1.20 when comparing the signals in
PSF immunoprecipitate arrays with those in control IgG
immunoprecipitate arrays, and they were considered to rep-
resent specific PSF-associated transcripts.
In Supplemental Table 1, we show a subset of selected
transcripts from the experimental data, including those
encoding proteins involved in tumor progression and
angiogenesis (PAI-RBP1), tumor suppression (NF2, LKB1),
cell–cell adhesion (-catenin), and cytoskeleton dynamics
(tubulin -6). To further validate these results, we per-
Figure 8. Enhanced RNA-binding ability of PSF in Hakai-overex-
pressing MDCK cells. (A) Cell lysates of parental and Hakai-over-
expressing MDCK cells were immunoprecipitated with control IgG
or anti-PSF antibody, followed by Western blotting with anti-PSF
antibody. It should be noted that PSF in Hakai-overexpressing cells
migrated more slowly in SDS-PAGE than that in parental cells, but
the identity of this modification is currently unknown. (B) Interac-
tion of PSF with mRNAs encoding PAI-RBP1, -catenin, NF2, LKB1,
and tubulin -6 was examined by RT-PCR after immunoprecipita-
tion with control IgG or anti-PSF antibody using parental and
Hakai-overexpressing MDCK cells. (C) Total RNA levels of the
indicated mRNAs in parental and Hakai-overexpressing MDCK
cells. The amount of mRNAs encoding PAI-RBP1, -catenin, NF2,
LKB1, tubulin -6, and -actin was examined by RT-PCR. 18S rRNA
was used for control RNA loading.
Figure 7. Interaction between Hakai and PSF. (A) Identification of
PSF as a novel Hakai-binding protein by affinity purification using
HEK293 cells lysates. Proteins bound to GST or GST-Hakai (N
terminus: amino acids 20-216) were examined by Coomassie protein
staining. Arrow and arrowhead indicate the position of PSF and
p54nrb, respectively. (B) Interaction between endogenous Hakai and
PSF proteins. HEK293 cell lysates were immunoprecipitated with
control IgG or anti-PSF antibody, followed by Western blotting with
anti-PSF and anti-Hakai antibodies. (C) Colocalization of Hakai and
PSF in the nucleus. The subcellular localization of Hakai and PSF
was examined in MCF-7 and MDCK cells using anti-Hakai and
anti-PSF antibodies. Bar, 10 m.
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formed RT-PCR using PSF immunoprecipitates from paren-
tal and Hakai-overexpressing MDCK cells (Figure 8A). In
Hakai-overexpressing cells, the amount of PSF-bound tran-
scripts was increased compared with that in parental cells
(Figure 8B), indicating a positive regulatory role of Hakai in
the RNA-binding capacity of PSF. Total amount of mRNAs
were not affected by overexpression of Hakai (Figure 8C).
The RNA-binding ability of another RNA-binding protein
HuR was not affected by overexpression of Hakai (Supple-
mental Figure S9), suggesting the specific effect of Hakai on
PSF. To ascertain this result, the role of Hakai in the RNA-
binding ability of PSF was examined in transformed epithe-
lial cell lines, MCF-7 cells (Figure 9A). Interestingly, we
found that the considerable amount of mRNAs bound to
PSF in MCF-7 cells (Figure 9B). Thus, the effect of knock-
down of Hakai on the interaction between PSF and mRNAs
was examined. Total amounts of mRNAs were not affected
by knockdown of Hakai (Figure 9C). On knockdown of
Hakai, PSF could no longer firmly interact with mRNAs
(Figure 9B), confirming that Hakai plays a crucial role in the
RNA-binding ability of PSF.
To examine the functional relation between Hakai and
PSF, we established Hakai-overexpressing MDCK cell lines
that stably express PSF shRNA. In these cells, expression of
PSF was knocked down by 60% (Figure 10A). BrdU incor-
poration analyses showed that the knockdown of PSF par-
tially suppressed the effect of Hakai overexpression on cell
proliferation (Figure 10B). PSF knockdown did not affect the
expression of E-cadherin in Hakai-overexpressing MDCK
cells (unpublished observation). Furthermore, transient ex-
pression of the N terminus of PSF that binds to Hakai but
lacks RNA-binding sites (Supplemental Figure S7) signifi-
Figure 9. Reduced RNA-binding ability of PSF in Hakai-knock-
down MCF-7 cells. (A) Cell lysates of MCF-7 cells transfected with
a Hakai siRNA or control nonsilencing oligo were immunoprecipi-
tated with control IgG or anti-PSF antibody, followed by Western
blotting with anti-PSF antibody. (B) Interaction of PSF with mRNAs
encoding PAI-RBP1, -catenin, NF2, LKB1, and tubulin -6 was
examined by RT-PCR after immunoprecipitation with control IgG
or anti-PSF antibody using MCF-7 cells transfected with a Hakai
siRNA or control nonsilencing oligo. (C) Total RNA levels of the
indicated mRNAs in MCF-7 cells transfected with a Hakai siRNA or
control nonsilencing oligo. The amount of mRNAs encoding PAI-
RBP1, -catenin, NF2, LKB1, tubulin -6, and -actin was examined
by RT-PCR. 18S rRNA was used for control RNA loading.
Figure 10. PSF is involved in the proliferative control in Hakai-
overexpressing MDCK cells. (A) Effect of PSF shRNA on PSF ex-
pression in Hakai-overexpressing MDCK cells. Cell lysates of Hakai-
overexpressing MDCK cells stably transfected with control shRNA or
PSF shRNA were examined by Western blotting with anti-PSF and
anti-GAPDH antibodies. (B) Effect of PSF shRNA on cell proliferation
in Hakai-overexpressing MDCK cells. Parental, Hakai-overexpress-
ing MDCK cells, or Hakai-overexpressing MDCK cells stably trans-
fected with PSF shRNA were labeled with BrdU and analyzed by
immunofluorescence with anti-BrdU antibody. Statistical analyses
indicate the significantly decreased BrdU incorporation in PSF
shRNA Hakai-overexpressing cells compared with Hakai-overex-
pressing cells (*p  0.01; n  3). Results are expressed as a percent-
age relative to Hakai-overexpressing cells, and are represented as
mean SD. (C) Effect of expression of the N terminus of PSF on cell
proliferation in Hakai-overexpressing MDCK cells. GFP, GFP-PSF
(full length), or GFP-PSF-N (amino acids 1-340) was transiently
expressed in Hakai-overexpressing MDCK cells. Cells were labeled
with BrdU and analyzed by immunofluorescence with anti-BrdU
antibody. Statistical analyses indicate the significantly decreased
BrdU incorporation in Hakai-overexpressing MDCK cells that ex-
press GFP-PSF-N (*p  0.001; n  3). Results are expressed as a
percentage relative to GFP-expressing cells and are represented as
mean  SD.
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cantly suppressed cell proliferation in Hakai-overexpressing
MDCK cells (Figure 10C). These data suggest an involve-
ment of PSF in the regulation of cell proliferation.
DISCUSSION
In this article, we show that Hakai is involved in the regu-
lation of not only cell–cell contacts but also cell proliferation.
Overexpression of Hakai in epithelial cells induces dramatic
morphological effects that are reminiscent of the epithelial–
mesenchymal transition. The expression level of E-cadherin
is specifically reduced and the strength of cell–cell contacts
is strongly decreased. The loss of cell–cell contacts is accom-
panied by increased protrusion formation. However, one of
the most obvious phenotypic changes is observed in cell
proliferation. On overexpression of Hakai, cells proliferate
two- to threefold faster. In contrast, there is a significant
decrease in the proliferation rate in cells expressing Hakai
siRNA. Close correlation between Hakai expression and
proliferation is also observed in two different human tissues.
Our data suggest that there are two proteins through which
Hakai may regulate cell proliferation: PSF and cyclin D1.
Expression of PSF shRNA or a dominant-negative PSF mu-
tant significantly suppresses proliferation of Hakai-overex-
pressing MDCK cells (Figure 10, B and C). The knockdown
of Hakai specifically affects the protein expression level of
cyclin D1 in MCF-7, HEK293, and MDA-MB231 cells (Figure
3C and Supplemental Figure S3C). These two proteins may
function independently, because overexpression of Hakai
does not affect the ability of PSF to interact with the mRNA
that encodes cyclin D1 (unpublished observation). We also
show that the expression of the Hakai mutant lacking the
RING-finger domain suppresses cell proliferation, suggest-
ing that E3 ubiquitin-ligase activity of Hakai is, at least
partially, involved in cell proliferation (Supplemental Figure
S4, A–D). This Hakai mutant is able to bind PSF (Supple-
mental Figure S4E), indicating that the interaction with PSF
itself cannot promote cell proliferation. We have obtained no
evidence showing that Hakai induces ubiquitination of PSF.
Thus, it is plausible that there are unidentified substrate
protein(s) that are involved in Hakai/PSF-mediated prolif-
erative control. It remains to be elucidated whether and how
PSF, cyclin D1, and E3 ubiquitin-ligase activity of Hakai are
functionally correlated.
There are several lines of evidence indicating that Hakai
can affect multiple cellular phenotypes in an E-cadherin–
independent manner. For example, MDCK cells expressing
E-cadherin shRNA do not extend spiky protrusions that are
seen in Hakai-overexpressing cells (unpublished observa-
tion). Overexpression and knockdown of Hakai affects cell
proliferation in NIH3T3 and HEK293 cells, respectively,
where no or little expression of E-cadherin is detected (Fig-
ure 3B and Supplemental Figure S3B). Thus, it is plausible
that Hakai fulfills its functions by interacting with other
proteins than E-cadherin. Here, we identify PSF as a novel
Hakai-binding protein. PSF has been recently shown to af-
fect multiple cellular processes (Shav-Tal and Zipori, 2002;
Kaneko et al., 2007; Cobbold et al., 2008); however, it is still
not clearly known which RNAs specifically interact with
PSF. By using cDNA arrays, we have determined several
transcripts that bind to PSF. Furthermore, we show that
Hakai regulates the interaction between PSF and its target
mRNAs. In the future, it needs to be further investigated
how the functions of PSF targets are affected by Hakai and
attributed to Hakai-mediated cellular processes.
Another observation is that Hakai localizes in the nucleus
as well as in the cytoplasm in cultured cell lines and human
tissues. On addition of HGF, cytoplasmic localization of Hakai
increases, indicating that subcellular localization of Hakai is
dynamically regulated; however, the molecular mechanisms
that regulate Hakai localization are not clear. It is interesting
that this enriched nuclear localization also was observed in
-transducin repeat-containing protein (-TrCP) (Davis et
al., 2002). -TrCP is an F-box-type E3 ubiquitin-ligase that
ubiquitinates many cytoplasmic proteins such as -catenin
and inhibitor of nuclear factor-B (Maniatis, 1999; Polakis
et al., 1999; Karin and Ben-Neriah, 2000). Despite its impor-
tant roles in the cytoplasm, -TrCP localizes predominantly
in the nucleus. In the nucleus it binds to a pseudosubstrate
hnRNP-U, and this interaction is responsible for the nuclear
localization of -TrCP (Davis et al., 2002), although its nu-
clear role is not clearly understood. In a similar way, Hakai
may also have nuclear binding protein(s) that regulate lo-
calization of Hakai.
By using immunohistochemistry, we have analyzed the
expression and localization of Hakai in several human can-
cer tissues. In colon cancer, the expression of Hakai is highly
enhanced both in the nucleus and cytoplasm. This enhanced
Hakai expression is also observed in benign colon adenoma
(unpublished observation), suggesting that Hakai may be
involved in the early stages of tumorgenesis by up-regulat-
ing cell proliferation. Similar up-regulation of Hakai is also
found in gastric carcinoma, whereas we have not observed
increased expression of Hakai in melanoma and glioblas-
toma cells (unpublished observation), indicating that up-
regulation of Hakai in cancer is cell type specific. In addi-
tion, we have shown that the knockdown of Hakai in
transformed epithelial cells significantly reduces the prolif-
eration rate. Together, these observations suggest that Hakai
can be a potential drug target in cancer treatment. Further
investigations of the physiological and pathological func-
tional roles of Hakai would lead us to a novel therapeutic
treatment for cancer.
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